.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Covington
Colorcon
Fuji
Argus Health
Accenture
US Department of Justice
Express Scripts
Harvard Business School
Baxter

Generated: December 13, 2017

DrugPatentWatch Database Preview

XOPENEX HFA Drug Profile

« Back to Dashboard

Which patents cover Xopenex Hfa, and when can generic versions of Xopenex Hfa launch?

Xopenex Hfa is a drug marketed by Sunovion and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-six patent family members in eighteen countries.

The generic ingredient in XOPENEX HFA is levalbuterol tartrate. There are nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the levalbuterol tartrate profile page.

Summary for XOPENEX HFA

Drug patent expirations by year for XOPENEX HFA

Pharmacology for XOPENEX HFA

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: XOPENEX HFA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: XOPENEX HFA

Country Document Number Estimated Expiration
Portugal1572622► Subscribe
Slovenia1572622► Subscribe
Cyprus1111330► Subscribe
Japan2006509802► Subscribe
South Korea20080103614► Subscribe
Poland377336► Subscribe
Canada2507572► Subscribe
Norway331649► Subscribe
Denmark1671942► Subscribe
Poland212725► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Argus Health
UBS
Teva
Mallinckrodt
Baxter
Fuji
QuintilesIMS
Chubb
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot